Close Menu

NEW YORK — Amoy Diagnostics said on Thursday that it has signed an agreement to develop a PCR-based companion diagnostic for Merck KGaA's cancer drug Tepmetko (tepotinib).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.